Almirall SA: and Happify Health launch digital therapeutic support for patients with psoriasis
Almirall and Happify Health Launch Digital Therapy Support for Psoriasis Patients
August 08, 2022
The partnership between Happify Health and Almirall kicks off with the launch of Claro, a digital wellness intervention for people with psoriasis looking to improve their mental wellbeing, in Spain, the UK and Italy.
An estimated 20-30% of patients with moderate to severe psoriasis also suffer from mental health issues, such as anxiety and depression.
Claro is the first iteration of Happify Health’s platform for people with psoriasis. It is available in English, Spanish, Italian and French.
BARCELONA, Spain, and NEW YORK, United States — May 24, 2022 – Today, happy healththe Intelligent Healing Company™, and Almirall, SA (BME:ALM), a global biopharmaceutical company focused on skin health, announced that Claro, a digital program developed through the two companies’ innovative partnership, is live and now available for psoriasis sufferers in Spain, Italy and the UK.
Claro was designed to improve the mental well-being of people with psoriasis by providing cognitive behavioral therapy, positive psychology, and mindfulness. Since launch, engagement rates on Claro have been high, with active users on the platform completing an average of 2.6 activities per week.
Psoriasis is one of the most common skin diseases in the world, affecting approximately 60 million people worldwide1. An estimated 20-30% of people with moderate to severe psoriasis worldwide also suffer from mental health issues like anxiety and depression.2. About 80% of people with psoriasis have mild to moderate symptoms, with direct healthcare costs for treating psoriasis exceeding $65 billion annually.
“At Almirall, we are proud to offer psoriasis patients a wide range of medications that cover the full spectrum of the disease, from mild to severe. Claro helps us fulfill our commitment to people with psoriasis, providing them with an enhanced solution for their well-being so they can get their lives back.“ said Dr. Volker Koscielny, MD, Chief Medical Officer of Almirall.
“Psoriasis is a significant burden in the daily life of 71% of people who suffer from it according to the National Psoriasis Foundation in the UK3,” said Theo Ahadome, Senior Vice President of Marketing at Happify Health.“A 2019 study in Maedica, the Journal of Clinical Medicine establishes a clear link between skin psychology and quality of life for people with psoriasis.3This partnership gives us the opportunity to study the effectiveness of digital programs in keeping psoriasis patients engaged during psoriasis treatment and improving their quality of life.“
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to meet the needs of patients through science to improve their lives. Our Noble Purpose is at the heart of our work: “To transform the world of patients by helping them realize their hopes and dreams for a healthy life“. We invest in differentiated and revolutionary medical dermatology products to bring our innovative solutions to patients who need them.
The company, founded in 1943 and based in Barcelona, is listed on the Spanish Stock Exchange and is a member of IBEX35 (ticker: ALM). Throughout its 79-year history, Almirall has always focused on patient needs. Currently, Almirall has a direct presence in 21 countries and strategic agreements in more than 70, with approximately 1,800 employees. The total turnover in 2021 was 836.5 million euros.
For more information, visit almirall.com
HL Richards, DG Fortune, CE Griffiths, CJ Main The contribution of perceptions of stigma to disability in patients with psoriasis J Psychosom Res., 50 (2001), pp. 11-15.
The prevalence of comorbid depression in patients with psoriasis is estimated to be between 20% and 30%, and rates as high as 62% have been reported. EA Dowlatshahi, M. Wakkee, LR Arends, T. Nijsten The prevalence and likelihood of depressive symptoms and clinical depression in patients with psoriasis: A systematic review and meta-analysis J Invest Dermatol., 134 (2014) , p. 1542-1551. M. Esposito, R. Saraceno, A. Giunta, M. Maccarone, S. ChimentiAn Italian study on psoriasis and depression Dermatology., 212 (2006), pp. 123-127.
Overview of the 2008 National Psoriasis Foundation survey. Available at: PTT-24087-quality-of-life-issues-and-measurement-in-patients-with-psor (researchgate.net)
Almirall S.A. published this content on August 08, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on Aug 08, 2022 10:24:09 AM UTC.
Public now 2022
Trends in Technical Analysis ALMIRALL, SA
|Short term||Middle term||Long term|
Evolution of the income statement
|Medium consensus||TO BUY|
|Number of analysts||11|
|Last closing price||€9.80|
|Average target price||€14.30|
|Average Spread / Target||45.9%|